From the Nasdaq MarketSite Studio, New to The Street airs TV Host Jane King’s interview with Alex Seelenberger, Chief Financial Officer of Vincerx Pharma, Inc. (NASDAQ: VINC) ($VINC). As a clinical-stage biopharmaceutical Company, Vincerx leverages its oncology expertise, focusing on developing new and advanced novel cancer drugs. Chemotherapies and radiation treatments are incredibly harmful to patients trying to beat cancer. These historical treatments come with many harmful toxic side effects where patients weigh the options over quality of life or life itself. Alex informs viewers about an upcoming class of drug treatments called antibody-drug conjugates (ADCs). These drugs target cancer, attaching and killing those cells. Unfortunately, FDA-approved ADCs in the marketplace still have risks, where toxicity still occurs, killing and destroying good cells/tissues. Vincerx’s world-class management and scientific teams with decades of experience, numerous drug approvals, and regulatory expertise are developing next-generation ADCs that aggressively attack targeted cancer cells but dramatically diminish toxicity and healthy cell/tissue destructions. The Company’s drug pipeline includes ADCs and small molecule drug conjugate (SMDC), all under development to combat different cancers with expected positive life-changing results for cancer patients. VIP236, an SMDC under development for treating advanced/metastatic solid tumors, has shown great lab results, and the developmental drug is in FDA Phase I clinical trial. Management expects data from the clinical to be forthcoming in 2024. Management recently entered an FDA Phase I clinical on VIP943, an ADC for treating certain types of leukemia, and they expect the published results of the study to come sometime in 2024. The Company is developing VIP924, a treatment for multiple malignancies, and VIP512, a combination drug agent. Vincerx Pharma is aggressively addressing the unmet medical needs of patients with cancer through novel and innovative drug treatments. The on-screen QR code is available during the show; download or visit Vincerx Pharma, Inc. – https://vincerx.com/.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://www.newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list